Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data | Scientific Reports
TAS-102 | Trifluridine | Tipiracil | CAS#733030-01-8 | CAS#183204-74-2 | CAS#70-00-8 | Thymidine Phhosphorylase Inhibitor | Cytotoxic Pyrimidine Analog | MedKoo
A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer - Cecchini - 2021 - Cancer - Wiley Online Library
Colon Cancer Treatment (PDQ®)–Health Professional Version - NCI
Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? - The Lancet Oncology
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Regorafenib TAS-102 or TAS-102 Regorafenib - ppt download
Combo Improves Survival in Refractory Colorectal Cancer | MedPage Today
Cost‐effectiveness Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer in the United States | Semantic Scholar
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer | NEJM
Relative tumor volume (RTV) of DLD-1 human colorectal tumor (a) and... | Download Scientific Diagram
Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third‑line or later chemotherapy regimen for refractory metastatic colorectal cancer
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data - Clinical Colorectal Cancer
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies - Godefridus J. Peters, 2015
![PDF] A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study) | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/efeb78a9cf4d98900513e2e2bb488055f524d020/3-Figure1-1.png "PDF] A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study) | Semantic Scholar")
PDF] A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study) | Semantic Scholar
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Essais cliniques sur le cancer gastro-intestinal | Study Connect
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
TAS 102 mechanism of action compared to 5-FU | Download Scientific Diagram
Chemorefractory Metastatic Colorectal Cancer: TAS ppt download
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies - Godefridus J. Peters, 2015
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer | NEJM
Colon Cancer Treatment (PDQ®)–Health Professional Version - NCI
In vitro antiproliferative effects of 5-fluorouracil (5-FU) (a) and... | Download Scientific Diagram
